Point72 Europe’s Gyre Therapeutics GYRE Stock Holding History

Point72 Europe’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-11,133	Closed	-$974K	–	22
2018 Q2	$974K	Buy	+11,133	New	+$1.95M	0.52%	20

Other funds holding GYRE

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Point72 Europe's GYRE Position: Q3 2018 in Review

Point72 Europe sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 11,133 shares — an estimated $974K sold.

Point72 Europe first reported a position in GYRE in Q2 2018 and held it in 1 quarter. The position peaked at $974K in Q2 2018. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

Point72 Europe reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
Point72 Europe sold 11,133 Gyre Therapeutics shares in Q3 2018, an estimated $974K.
Point72 Europe first reported a position in Gyre Therapeutics in Q2 2018 and held it in 1 quarter.
Point72 Europe's Gyre Therapeutics position peaked at $974K in Q2 2018.
70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Point72 Europe's 13F filing for Q3 2018, filed 14 Nov 2018.